Präzisionsmedizin bei genetischer Epilepsie und Entwicklungsenzephalopathien (DEEs)
Die Präzisionsmedizin bei neurologischen Entwicklungsstörungen und epileptischen Enzephalopathien (DEEs) zielt darauf ab, die pharmakologische Behandlung auf den pathophysiologischen und molekularen Mechanismus auszurichten, der der genetischen Variante des Patienten zugrunde liegt, und so unwirksame oder schädliche Therapien zu vermeiden.
Klinische Aufschlüsselung der dargestellten Therapieansätze
Die wichtigsten molekularen Kategorien und therapeutischen Ziele, die in der Tabelle dargestellt sind, sind nachstehend aufgeführt:
1. Natrium- und Kaliumkanalopathien
- SCN1A (Dravet-Syndrom – Funktionsverlust): Präzisionsansatz mit Fenfluramin, Cannabidiol, Stiripentol, Clobazam und Valproat. Genauigkeitswarnung: Natriumkanalblocker (Carbamazepin, Phenytoin, Lamotrigin) sind aufgrund des Risikos einer schweren Verschlechterung und refraktärer Anfälle formal kontraindiziert.
- SCN2A und SCN8A (Gain of Function-Varianten im frühen Debüt): Bevorzugte Angabe von Natriumkanalblocker in hohen Dosen (Phenytoin, Carbamazepin), die die Übererregbarkeit der Membran wiederherstellen.
- KCNQ2 / KCNQ3 (Kv7.2/Kv7.3 Kaliumkanäle): Selektive Öffnung von K+-Kanälen durch Retigabin (Ezogabin) und günstige Reaktion auf Natriumblocker wie Carbamazepin in frühen Phasen.
- KCNT1 (Na+-abhängige Kaliumkanäle): Verwendung von Chinidin als spezifischer Off-Label-Modulator bei refraktären fokalen Epilepsien von Migranten im Kindesalter.
2. Stoffwechsel- und Gehirntransportstörungen
- SLC2A1 (Brain Glucose Transporter GLUT1-Mangel): Obligatorische Substitutionstherapie Ketogene Diät früh, Bereitstellung von Ketonkörpern als alternatives Energiesubstrat für das Gehirn zu Glukose.
- ALDH7A1 / PNPO (Pyridoxin-abhängige Epilepsien): Spezifische lebenslange Ergänzung mit Pyridoxin (Vitamin B6) o Pyridoxal-5′-phosphat (PLP).
3. mTORopathien und Proliferation/Signalwege
- TSC1/TSC2 (Tuberöse Sklerose-Komplex) und DEPDC5/NPRL2/NPRL3 (GATOR1-Komplex): Hyperaktivierung der intrazellulären mTOR-Kaskade. Gezielte Ansprache mit mTOR-Inhibitoren (Everolimus, Sirolimus) zur Kontrolle von Anfällen und damit verbundenen fokalen kortikalen Dysplasien.
4. Modulatoren von Rezeptoren und synaptischen Signalwegen
- GRIN2A / GRIN2B (NMDA-Rezeptor-Untereinheiten): Allosterische Modulation und Blockade von NMDA-Rezeptoren durch Memantin in Varianten mit Funktionsgewinn.
- PCDH19 (Protocadherin 19): Neurosteroidmodulierende Therapien (Ganaxolon) und spezifische Hormonprotokolle.
Literaturverzeichnis
19955111
{19955111:6YYVTK6C}
1
Vancouver
50
Standard
7473
https://neuropediatoolkit.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226YYVTK6C%22%2C%22library%22%3A%7B%22id%22%3A19955111%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Beltr%5Cu00e1n-Corbellini%20et%20al.%22%2C%22parsedDate%22%3A%222022-02-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBeltr%26%23xE1%3Bn-Corbellini%20%26%23xC1%3B%2C%20Aledo-Serrano%20%26%23xC1%3B%2C%20M%26%23xF8%3Bller%20RS%2C%20P%26%23xE9%3Brez-Palma%20E%2C%20Garc%26%23xED%3Ba-Morales%20I%2C%20Toledano%20R%2C%20et%20al.%20Epilepsy%20Genetics%20and%20Precision%20Medicine%20in%20Adults%3A%20A%20New%20Landscape%20for%20Developmental%20and%20Epileptic%20Encephalopathies.%20Front%20Neurol%20%5BInternet%5D.%202022%20Feb%2017%20%5Bcited%202026%20June%2015%5D%3B13.%20Available%20from%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Fjournals%5C%2Fneurology%5C%2Farticles%5C%2F10.3389%5C%2Ffneur.2022.777115%5C%2Ffull%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Fjournals%5C%2Fneurology%5C%2Farticles%5C%2F10.3389%5C%2Ffneur.2022.777115%5C%2Ffull%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epilepsy%20Genetics%20and%20Precision%20Medicine%20in%20Adults%3A%20A%20New%20Landscape%20for%20Developmental%20and%20Epileptic%20Encephalopathies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1lvaro%22%2C%22lastName%22%3A%22Beltr%5Cu00e1n-Corbellini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1ngel%22%2C%22lastName%22%3A%22Aledo-Serrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rikke%20S.%22%2C%22lastName%22%3A%22M%5Cu00f8ller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Palma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Garc%5Cu00eda-Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Toledano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil-Nagel%22%7D%5D%2C%22abstractNote%22%3A%22This%20review%20aims%20to%20provide%20an%20updated%20perspective%20of%20epilepsy%20genetics%20and%20precision%20medicine%20in%20adult%20patients%2C%20with%20special%20focus%20on%20developmental%20and%20epileptic%20encephalopathies%20%28DEEs%29%2C%20covering%20relevant%20and%20controversial%20issues%2C%20such%20as%20defining%20candidates%20for%20genetic%20testing%2C%20which%20genetic%20tests%20to%20request%20and%20how%20to%20interpret%20them.%20A%20literature%20review%20was%20conducted%2C%20including%20findings%20in%20the%20discussion%20and%20recommendations.%20DEEs%20are%20wide%20and%20phenotypically%20heterogeneous%20electroclinical%20syndromes.%20They%20generally%20have%20a%20pediatric%20presentation%2C%20but%20patients%20frequently%20reach%20adulthood%20still%20undiagnosed.%20Identifying%20the%20etiology%20is%20essential%2C%20because%20there%20lies%20the%20key%20for%20precision%20medicine.%20Phenotypes%20modify%20according%20to%20age%2C%20and%20although%20deep%20phenotyping%20has%20allowed%20to%20outline%20certain%20entities%2C%20genotype-phenotype%20correlations%20are%20still%20poor%2C%20commonly%20leading%20to%20long-lasting%20diagnostic%20odysseys%20and%20ineffective%20therapies.%20Recent%20adult%20series%20show%20that%20the%20target%20patients%20to%20be%20identified%20for%20genetic%20testing%20are%20those%20with%20epilepsy%20and%20different%20risk%20factors.%20The%20clinician%20should%20take%20active%20part%20in%20the%20assessment%20of%20the%20pathogenicity%20of%20the%20variants%20detected%2C%20especially%20concerning%20variants%20of%20uncertain%20significance.%20An%20accurate%20diagnosis%20implies%20precision%20medicine%2C%20meaning%20genetic%20counselling%2C%20prognosis%2C%20possible%20future%20therapies%2C%20and%20a%20reduction%20of%20iatrogeny.%20Up%20to%20date%2C%20there%20are%20a%20few%20tens%20of%20gene%20mutations%20with%20additional%20concrete%20treatments%2C%20including%20those%20with%20restrictive%5C%2Fsubstitutive%20therapies%2C%20those%20with%20therapies%20modifying%20signaling%20pathways%2C%20and%20channelopathies%2C%20that%20are%20worth%20to%20be%20assessed%20in%20adults.%20Further%20research%20is%20needed%20regarding%20phenotyping%20of%20adult%20syndromes%2C%20early%20diagnosis%2C%20and%20the%20development%20of%20targeted%20therapies.%22%2C%22date%22%3A%222022-02-17%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffneur.2022.777115%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Fjournals%5C%2Fneurology%5C%2Farticles%5C%2F10.3389%5C%2Ffneur.2022.777115%5C%2Ffull%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221664-2295%22%2C%22language%22%3A%22English%22%2C%22collections%22%3A%5B%22LHRY9URB%22%5D%2C%22dateModified%22%3A%222026-06-15T16%3A09%3A49Z%22%7D%7D%5D%7D
1.
Beltrán-Corbellini Á, Aledo-Serrano Á, Møller RS, Pérez-Palma E, García-Morales I, Toledano R, et al. Epilepsiegenetik und Präzisionsmedizin bei Erwachsenen: Eine neue Perspektive für Entwicklungs- und epileptische Enzephalopathien. Front Neurol [Internet]. 17. Februar 2022 [zitiert am 15. Juni 2026];13. Verfügbar unter: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.777115/full